Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | NMT2 | O60551 | 1/20 | 0.47 |
| ▸ | NMT1 | P30419 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | FURIN | P09958 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527293 | 1.00 | NOD1 (0.58) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL30985184 | 0.98 | NOD1 (0.60) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL6129561 | 0.93 | NOD1 (0.61) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL2508780 | 0.93 | NOD1 (0.61) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL20529374 | 0.90 | NMT2 (0.43) | NOD1FOLH1NMT2NMT1CPB2 | |
| SCHEMBL21330513 | 0.90 | NOD1 (0.68) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL2512125 | 0.89 | FOLH1 (0.53) | NOD1FOLH1NMT2NMT1CPB2 | |
| SCHEMBL30512604 | 0.89 | FOLH1 (0.53) | NOD1FOLH1NMT2NMT1CPB2 | |
| SCHEMBL29451703 | 0.89 | FOLH1 (0.60) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL29451463 | 0.89 | FOLH1 (0.60) | NOD1FOLH1NMT2NMT1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206261-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CLAVULANIC ACID OR DERIVATIVE THEREOF FOR THE TREATMENT OF BEHAVIORAL DISEASES | REVAAX PHARMACEUTICALS LLC (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1212055-A4 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | REVAAX PHARMACEUTICALS LLC (US) | 2005-09-07 | — | — | EP | claimed |
| US-6627625-B1 | Beta-lactam antibiotics and beta -lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter by anxiolytic and antiaggressive behavior modification ans enhanced cognition | REVAAX PHARMACEUTICALS, LLC | 2003-09-30 | — | — | US | claimed |
| JP-2003506490-A | — | — | 2003-02-18 | — | — | JP | claimed |
| EP-1212055-A1 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | Revaax Pharmaceuticals LLC (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001012184-A1 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | REVAAX PHARMACEUTICALS, LLC (US) | 2001-02-22 | — | — | WO | claimed |
| US-20250037787-A1 | CONCENTRATION BOUNDS IN LARGE NETWORKS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-01-30 | — | — | US | disclosed |
| US-20150094229-A1 | METHODS FOR THE SCREENING OF ANTIBACTERIAL SUBSTANCES | UNIVERSITE RENE DESCARTES (FR) | 2015-04-02 | — | — | US | disclosed |
| EP-1212055-B1 | Neurotherapeutic composition comprising a beta-lactam compound | REVAAX PHARMACEUTICALS LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2305251-A2 | Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder | Revaax Pharmaceuticals LLC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7842683-B2 | Neurotherapeutic compositions and method | REVAAX PHARMACEUTICALS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100249090-A1 | NEUROTHERAPEUTIC COMPOSITION AND METHOD THEREFOR | KOPPEL GARY A | 2010-09-30 | — | — | US | disclosed |
| US-20090311714-A1 | Methods for the Screening of Antibacterial Substances | UNIVERSITE RENE DESCARTES (FR) | 2009-12-17 | — | — | US | disclosed |
| CN-1382047-A | Compositions and methods for treating neuropathy | REVAAX PHARMACEUTICALS LLC (US) | 2002-11-27 | — | — | CN | disclosed |
| WO-2002064087-A2 | NEUROTHERAPEUTIC USE OF CARBOXYPEPTIDASE INHIBITORS | REVAAX PHARMACEUTICALS, LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1212055-A1 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | Revaax Pharmaceuticals LLC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1206261-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CLAVULANIC ACID OR DERIVATIVE THEREOF FOR THE TREATMENT OF BEHAVIORAL DISEASES | Revaax Pharmaceuticals LLC (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020028761-A1 | Neurotherapeutic use of carboxypeptidase inhibitors | REVAAX PHARMACEUTICALS, LLC | 2002-03-07 | — | — | US | disclosed |
| WO-2001012171-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CLAVULANIC ACID OR DERIVATIVE THEREOF FOR THE TREATMENT OF BEHAVIORAL DISEASES | REVAAX PHARMACEUTICALS, LLC (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2001012184-A1 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | REVAAX PHARMACEUTICALS, LLC (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028761-A1 | Neurotherapeutic use of carboxypeptidase inhibitors | THOP1, DPEP1, PREP | NOD1 1895/4885FOLH1 8/4885NMT2 626/4885 |
| US-20100249090-A1 | NEUROTHERAPEUTIC COMPOSITION AND METHOD THEREFOR | PREP, ANPEP, MME | NOD1 3321/4885FOLH1 19/4885NMT2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.